Publicaciones en las que colabora con Ovidio Muñiz Grijalvo (29)

2024

  1. Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study

    American Journal of Preventive Cardiology, Vol. 17

  2. Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 11, pp. 811-823

  3. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study

    Circulation. Cardiovascular imaging, Vol. 17, Núm. 1, pp. e016206

  4. Estándares de la Sociedad Española de Arteriosclerosis 2024 para el control global del riesgo vascular

    Clínica e investigación en arteriosclerosis, Vol. 36, Núm. 3, pp. 133-194

  5. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

    The Lancet, Vol. 403, Núm. 10421, pp. 55-66

  6. Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 9, pp. 643-652

2023

  1. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

    Circulation, Vol. 147, Núm. 19, pp. 1436-1443

  2. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

    The Lancet

  3. PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk

    International Journal of Molecular Sciences, Vol. 24, Núm. 3

  4. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328

2022

  1. A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort

    European Journal of Preventive Cardiology, Vol. 29, Núm. 5, pp. 795-801

  2. Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?

    Current Atherosclerosis Reports, Vol. 24, Núm. 6, pp. 427-434

  3. SEA 2022 Standards for Global Control of Cardiovascular Risk

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 3, pp. 130-179

2021

  1. Adherence to a Mediterranean diet, dyslipidemia and inflammation in familial hypercholesterolemia

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 31, Núm. 7, pp. 2014-2022

  2. Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study

    Atherosclerosis, Vol. 317, pp. 52-58

  3. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience

    Journal of Clinical Lipidology, Vol. 15, Núm. 4, pp. 584-592

  4. Familial chylomicronemia and multifactorial chylomicronemia

    Clinica e Investigacion en Arteriosclerosis, Vol. 33, pp. 56-62

  5. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

    The Lancet, Vol. 398, Núm. 10312, pp. 1713-1725

  6. Lipoprotein(a), LDL-cholesterol, and hypertension: Predictors of the need for aortic valve replacement in familial hypercholesterolaemia

    European Heart Journal, Vol. 42, Núm. 22, pp. 2201-2211

  7. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia

    JACC: Cardiovascular Imaging, Vol. 14, Núm. 12, pp. 2414-2424